Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 21INDUSTRY 5UNKNOWN 4OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Triple Negative Breast Neoplasms 1Small Cell Lung Cancer Extensive Stage 1Pathologic Complete Response 1Oesophagogastric Cancer 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell, Marginal Zone 1HR+/HER2- Breast Cancer 1Congenital Abnormalities 1Breast Neoplasms 1

Interventions

camrelizumab 2Injections 2toripalimab 1epigallocatechin gallate 1atezolizumab 1Zinc 1Tablets 1Quercetin 1Nivolumab 1Metformin 1Imatinib Mesylate 1Gemcitabine 1Everolimus 1Epirubicin 1Docetaxel 1Cisplatin 1Carboplatin 1Capecitabine 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Triple Negative Breast Neoplasms × Epirubicin × Clear all
NCT04213898 2019-12-30

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Henan Cancer Hospital

Phase 1/2 Unknown
39 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡